ActiveCare+S.F.T. effectively reduces the risk of blood clot formation and prevents deep vein thrombosis (DVT) and venous thromboembolism (VTE) without the use of medications that are associated with an increased risk of bleeding.
It works by gently applying compression to your legs, increasing the speed of blood flow in the veins and reducing the risk of clot formation. S.F.T. stands for Synchronized Flow Technology, which enables the synchronization of the device compression to a specific phase of the respiratory-related venous phasic flow.
Its portable size, lightweight mobility, and ease of use provide continuous 24-hour protection. It is powered by a rechargeable battery, allowing you to quietly and comfortably move while wearing the device for extended periods of time.
The S.A.F.E Study
ActiveCare+S.F.T. was recently compared with Enoxaparin, a blood thinning medication, in a clinical trial that took place in 9 leading US medical centers, known as the S.A.F.E. study.
The S.A.F.E. Study was conducted on more than 400 patients who underwent Total HipArthroplasty surgery and completed full recommended ten-day prophylaxis treatment both in-hospital and post discharge.
The S.A.F.E. Study is the first and only study which compares head to head a device with a medication. The results were that patients using the ActiveCare device had similar protection against thromboembolism as with the use of Enoxaparin, but had a lower incidence in major bleeding. The ActiveCare device has been proven effective and is widely in use for DVT prevention.
*Source: Medical Compression Systems 2012 http://www.mcsmed.com/activecare_sft_2.html